Sulbactam Acid Pharma Grade API is the penicillanic acid sulfone (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide, CAS 68373-14-8, molecular formula C8H11NO5S, molecular weight 233.24 g/mol. The product is supplied as a white to off-white crystalline powder and is used as an irreversible β-lactamase inhibitor in fixed-dose combination with ampicillin or cefoperazone. The inhibitory mechanism involves acylation of the serine active site in Ambler class A β-lactamases, preventing hydrolysis of the partner β-lactam antibiotic. Distinct from clavulanic acid and tazobactam, sulbactam also possesses direct antibacterial activity against Acinetobacter baumannii through binding to penicillin-binding proteins at higher exposures. The API is manufactured in non-sterile oral grade, low-endotoxin injectable grade, and sterile injectable grade. Unmodified sulbactam acid has low oral permeability; oral tablet, capsule, and granule products therefore commonly employ sultamicillin tosylate, a mutual prodrug that releases ampicillin and sulbactam after esterase-mediated hydrolysis. For injectable processing, the acid is either neutralized with sodium bicarbonate in situ or supplied as the corresponding sodium salt to achieve a suitable reconstitution pH.

Model designations vary by manufacturer, but they generally distinguish particle size, residual solvent profile, pyrogen status, and packaging configuration. Low-endotoxin grade is tested by USP <85>; sterile grade is aseptically processed under EU GMP Annex 1 and qualified for 0.22 µm filtration using ASTM F838-20. The non-sterile grade used in oral solid intermediates is released with microbial enumeration per USP <61> and USP <62>. Bulk packing uses double low-density polyethylene liners inside HDPE drums or fiber drums with desiccant, with re-test intervals assigned from manufacturer stability data.

What Compendial Release Tests Apply to Sulbactam Acid API Across Oral and Injectable Grades?

Release testing is structured to satisfy ICH Q3A for organic impurities, ICH Q3C for residual solvents, and ICH Q3D for elemental impurities. The primary assay is reversed-phase HPLC with UV detection using a C18 or equivalent column; system suitability follows USP <621>. Identification relies on mid-infrared absorption spectroscopy against a qualified reference standard and HPLC retention time concordance. Residual solvents are measured by gas chromatography with headspace sampling using conditions aligned to USP <467> and Ph. Eur. 2.4.24. Water content is determined by Karl Fischer titration, and residue on ignition is controlled by USP <281>. Non-sterile oral API is evaluated for microbial enumeration by USP <61> and specified microorganisms by USP <62>. Injectable grades require bacterial endotoxin testing per USP <85>, with the acceptance limit derived from the maximum intended dose and route of administration. Particle size distribution is characterized by laser diffraction according to USP <429>; the D10, D50, and D90 targets are product-specific and are correlated with content uniformity in low-dose tablet and capsule manufacturing.

Elemental impurity risk assessments for Sulbactam Acid consider the manufacturing route, catalysts, water quality, and final crystallization solvents. Typical controls address the elements listed in ICH Q3D, with permitted daily exposure limits calculated separately for oral and parenteral grades. Residual solvents from final crystallization are generally limited to Class 3 solvents, while any Class 2 solvents are controlled below ICH Q3C options. Vendor documentation should confirm that a nitrosamine risk assessment has been performed according to current EMA and FDA guidance, with confirmatory testing where indicated. The table below summarizes the core release matrix.

Powder Flow, Granulation, and Compression Behavior in Oral Solid Dosage Manufacturing

Direct compression of unesterified Sulbactam Acid API is not the primary commercial route for oral tablets or capsules because the crystalline powder can exhibit cohesive flow and low bulk density. Formulators typically densify the API by dry granulation using a roller compactor, or by wet granulation in a high-shear granulator followed by fluid-bed drying. The granulation end point is commonly controlled by loss on drying, sieve fraction analysis, and tapped density according to USP <616>. For tablet compression, a rotary tablet press equipped with a gravity feed frame and pre-compression station is used; tabletability is assessed by hardness and friability per USP <1216>. Content uniformity is evaluated according to USP <905> to ensure that low-dose API granules remain uniformly distributed across a batch. Capsule filling of sulbactam acid-containing granules is performed on an automatic capsule machine with tamping pins or dosator nozzles; flow properties are improved by the addition of colloidal silicon dioxide at levels not exceeding 0.5 wt% and magnesium stearate at levels not exceeding 1.0 wt%, with the understanding that extended hydrophobic lubricant blending reduces tensile strength. Published data for the direct compression of unmodified sulbactam acid is limited, so formulation and process parameters are established through product-specific development rather than compendial specifications.

For oral granules and sachet presentations, sulbactam acid is most frequently used as an intermediate in the synthesis of sultamicillin tosylate, rather than as the sole active ingredient. In this configuration, the final oral product delivers ampicillin and sulbactam in a 1:1 molar ratio after hydrolysis. The use of sultamicillin tosylate addresses the low oral bioavailability of sulbactam acid while maintaining equivalent β-lactamase inhibition in the systemic circulation. Formulators evaluating unmodified sulbactam acid for oral granule filling must characterize permeability limitations using a suitable in vitro model; published data for bioequivalence of unmodified sulbactam acid oral products is limited. Granule formulations for sachet filling require an additional particle-size upper limit to prevent segregation during automated filling; sieve fractions above 850 µm are routinely removed, and the retained fraction is monitored. Uniformity of mass of filled sachets is tested according to USP <905> for single-dose preparations.

Low-endotoxin Sulbactam Acid intended for injectable manufacture is subjected to bacterial endotoxin control according to USP <85>, with the limit derived from the maximum daily dose and the route-specific threshold of 5.0 EU/kg. Sterile Sulbactam Acid API is produced under EU GMP Annex 1 conditions, with critical Grade A environments monitored for viable and non-viable particulates. Injectable compounding frequently uses the acid as an intermediate for in situ neutralization with sodium bicarbonate, producing sulbactam sodium in the compounding vessel prior to final dilution. The neutralized solution is aseptically filtered through a 0.22 µm membrane filter qualified for bacterial retention according to ASTM F838-20. Container-closure integrity is verified using vacuum decay or high-voltage leak detection methods aligned to USP <1207>. The sodium salt, rather than the free acid, is preferred for parenteral reconstitution because it provides higher water solubility and permits faster dissolution in intravenous diluents. Particulate matter in injectable solutions is controlled by USP <788>; subvisible particles ≥10 µm and ≥25 µm are assessed after reconstitution. Sterility is tested by membrane filtration per USP <71>, with validation of bacteriostasis and fungistasis. Incompatibility is documented with strong oxidizing agents and strongly alkaline solutions, which accelerate β-lactam hydrolysis. Reconstituted solutions should be used according to validated in-use stability data; unpreserved solutions are not intended for extended storage at room temperature because of hydrolytic degradation and microbial growth risk.

When Sulbactam Acid Is Selected Over Clavulanic Acid or Tazobactam for β-Lactamase Inhibition

Sulbactam acid differs from clavulanic acid in core pharmacophore: sulbactam is a penicillanic acid sulfone, while clavulanic acid is a clavam oxapenam. Tazobactam is also a penicillanic acid sulfone, but it carries a 1,2,3-triazolylmethyl substitution that alters its molecular weight and β-lactamase inhibition spectrum. These structural differences translate into different partner pairing and clinical placement. Sulbactam is paired mainly with ampicillin or cefoperazone; clavulanic acid is paired with amoxicillin; tazobactam is paired with piperacillin. When the target product profile includes direct antibacterial activity against Acinetobacter baumannii, sulbactam is selected at high doses in ampicillin-sulbactam or cefoperazone-sulbactam combinations because it binds penicillin-binding proteins in Acinetobacter spp., an effect not shared to a clinically relevant extent by clavulanic acid or tazobactam. Clavulanic acid is more potent than sulbactam as an inhibitor of certain TEM-1 and SHV-1 β-lactamases on a molar basis in some published enzyme kinetics assays, but clavulanate lacks clinically meaningful direct anti-Acinetobacter activity. Sulbactam is not a broad-spectrum inhibitor of Ambler class C or class D enzymes; avibactam, a non-β-lactam diazabicyclooctane, inhibits selected class C and class D β-lactamases but does not provide the same direct anti-Acinetobacter activity. The choice of sulbactam acid API is therefore based on the intended β-lactam partner, the β-lactamase epidemiology of the target pathogens, and the regulatory precedent for the combination product.

Hydrolytic Degradation Pathways and Moisture Management in Bulk Storage

Hydrolytic degradation of the β-lactam ring is the principal stability concern for Sulbactam Acid API. The reaction rate increases in aqueous solvents, in alkaline media, and in the presence of strong nucleophiles. Bulk storage is therefore maintained at controlled room temperature not exceeding 25 °C, with relative humidity below 60% and double polyethylene-lined HDPE or fiber drums containing desiccant. Residual water is limited by Karl Fischer titration, and the API should not be exposed to prolonged open handling in uncontrolled humidity. For solid oral formulations, direct blending with basic excipients such as sodium bicarbonate is avoided or followed by immediate processing because residual moisture can initiate solid-state hydrolysis during storage. Stability-indicating HPLC is used to monitor degradation products across the re-test interval; the re-test period is assigned from manufacturer long-term stability data under the specified packaging configuration. Compatibility with common excipients, including microcrystalline cellulose, croscarmellose sodium, and magnesium stearate, is established through forced-degradation studies followed by assay and impurity profiling. These limitations apply to the free acid; sulbactam sodium used in injectable manufacture has a different hygroscopicity profile and should be evaluated under separate storage protocols.